Alpha-lipoic acid and vitamin B complex slow down the changes in mice diabetic cardiomyopathy

Târtea, Georgică Costinel; Florescu, Diana Ruxandra; Mihailovici, Alexandru Radu; Donoiu, I; Istrătoaie, Octavian

doi:10.47162/rjme.61.2.22

Cited by 4 publications

(4 citation statements)

References 42 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B vitamins are usually used as antioxidants because of their excellent antioxidant activities. α-LA is a coenzyme that belongs to the vitamin B family that exists in the mitochondria [19]. Some researchers have demonstrated that α-LA (often called a super antioxidant) reduces the amount of free radicals or ROS in the body, for example, NO, hydrogen peroxide and hydroxyl radical [20].…”

Section: Introductionmentioning

confidence: 99%

Protective Effects of α-Lipoic Acid and Chlorogenic Acid on Cadmium-Induced Liver Injury in Three-Yellow Chickens

Shi

Zou

et al. 2021

Animals

View full text Add to dashboard Cite

Cadmium (Cd) is a type of noxious heavy metal that is distributed widely. It can severely injure the hepatocytes and cause liver dysfunction by inducing oxidative stress and mitochondrial damage. We evaluated the protective effects of α-lipoic acid (α-LA) or chlorogenic acid (CGA) and their combination on counteracting cadmium toxicity in vivo in three-yellow chickens. For three months, CdCl2 (50 mg/L) was administrated through their drinking water, α-LA (400 mg/kg) was added to feed and CGA (45 mg/kg) was employed by gavage. The administration of Cd led to variations in growth performance, biochemical markers (of the liver, kidney and heart), hematological parameters, liver histopathology (which suggested hepatic injury) and ultrastructure of hepatocytes. Some antioxidant enzymes and oxidative stress parameters showed significant differences in the Cd-exposure group when compared with the control group. The groups treated with Cd and administrated α-LA or CGA showed significant amelioration with inhibited mitochondrial pathway-induced apoptosis. Combining both drugs was the most effective in reducing Cd toxicity in the liver. In summary, the results demonstrated that α-LA and CGA may be beneficial in alleviating oxidative stress induced by oxygen free radicals and tissue injury resulting from Cd-triggered hepatotoxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Protective Effects of α-Lipoic Acid and Chlorogenic Acid on Cadmium-Induced Liver Injury in Three-Yellow Chickens

Shi

Zou

et al. 2021

Animals

View full text Add to dashboard Cite

show abstract

“…Regarding induction and assessment of diabetes mellitus and therapeutic protocols in mice, diabetes was induced by a single intraperitoneal injection and the administration of 150 mg streptozotocin/kg body weight, between 8 and 10 weeks of life, as in two of our previous studies [58,59]. Diabetes mellitus was diagnosed according to the criteria of the American Diabetes Association (ADA) [60].…”

Section: Animalsmentioning

confidence: 99%

Chitosan Versus Dapagliflozin in a Diabetic Cardiomyopathy Mouse Model

Târtea,

Popa-Wagner,

Sfredel

et al. 2024

IJMS

View full text Add to dashboard Cite

Diabetes mellitus is a metabolic disorder with global economic implications that can lead to complications such as diabetic cardiomyopathy. The aim of this study was to compare the effects of chitosan versus dapagliflozin in mouse diabetic cardiomyopathy. We used 32 C57Bl/6 male mice aged between 8 and 10 weeks, which were randomly divided into Control—without diabetes mellitus (DM), type 1 DM (T1DM), T1DM + Chitosan, and T1DM + Dapapgliflozin groups. We induced diabetes with streptozotocin and treated the animals for 12 weeks. The analysis showed a reduction in intramyocardial fibrosis in the T1DM + Dapapgliflozin compared to T1DM animals. In T1DM + CHIT, a reduction in intramyocardial fibrosis was observed although, accordingly, there was also no significant decrease in blood glucose. The level of oxidative stress was reduced in the groups of treated animals compared to T1DM. All these observed changes in the structure and function of hearts were highlighted in the echocardiographic examination. In the treated groups, there was delayed appearance of left ventricular (LV) hypertrophy, a slight decrease in the ejection fraction of the LV, and an improved diastolic profile. The results demonstrate that chitosan has promising effects on diabetic cardiomyopathy that are comparable to the beneficial effects of dapagliflozin.

show abstract

“…In addition, it is also obtained from plant and animal sources and can also be given as a dietary supplement ( Shay et al, 2009 ). A growing body of preclinical and clinical evidence shows that ALA effectively improves glucose homeostasis and lipid profile in both T1DM and T2DM and also plays a cardioprotective role against development and/or progression of DCM through its potent multifunctional antioxidant property ( Strödter et al, 1995 ; Midaoui et al, 2003 ; Li et al, 2009 ; Lee et al, 2012; Li et al, 2012 ; Lee et al, 2017 ; Akbari et al, 2018 ; Târtea et al, 2020 ). It is also beneficial in clinical and experimental models of other diabetic complications such as diabetic peripheral neuropathy ( Lee T. H. et al, 2012 ; Ziegler et al, 2016 ; Verma, 2018 ), diabetic nephropathy ( Chang et al, 2007 ; Lee et al, 2009 ) and gestational diabetes mellitus ( Aslfalah et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Combination Therapy of Alpha-Lipoic Acid, Gliclazide and Ramipril Protects Against Development of Diabetic Cardiomyopathy via Inhibition of TGF-β/Smad Pathway

et al. 2022

View full text Add to dashboard Cite

Background: Diabetic cardiomyopathy (DCM) is a major long-term complication of diabetes mellitus, accounting for over 20% of annual mortality rate of diabetic patients globally. Although several existing anti-diabetic drugs have improved glycemic status in diabetic patients, prevalence of DCM is still high. This study investigates cardiac effect of alpha-lipoic acid (ALA) supplementation of anti-diabetic therapy in experimental DCM.Methods: Following 12 h of overnight fasting, 44 male Sprague Dawley rats were randomly assigned to two groups of healthy control (n = 7) and diabetic (n = 37) groups, and fasting blood glucose was measured. Type 2 diabetes mellitus (T2DM) was induced in diabetic group by intraperitoneal (i.p.) administration of nicotinamide (110 mg/kg) and streptozotocin (55 mg/kg). After confirmation of T2DM on day 3, diabetic rats received monotherapies with ALA (60 mg/kg; n = 7), gliclazide (15 mg/kg; n = 7), ramipril (10 mg/kg; n = 7) or combination of the three drugs (n = 7) for 6 weeks while untreated diabetic rats received distilled water and were used as diabetic control (n = 9). Rats were then sacrificed, and blood, pancreas and heart tissues were harvested for analyses using standard methods.Results: T2DM induction caused pancreatic islet destruction, hyperglycemia, weight loss, high relative heart weight, and development of DCM, which was characterized by myocardial degeneration and vacuolation, cardiac fibrosis, elevated cardiac damage markers (plasma and cardiac creatine kinase-myocardial band, brain natriuretic peptide and cardiac troponin I). Triple combination therapy of ALA, gliclazide and ramipril preserved islet structure, maintained body weight and blood glucose level, and prevented DCM development compared to diabetic control (p < 0.001). In addition, the combination therapy markedly reduced plasma levels of inflammatory markers (IL-1β, IL-6 and TNF-α), plasma and cardiac tissue malondialdehyde, triglycerides and total cholesterol while significantly increasing cardiac glutathione and superoxide dismutase activity and high-density lipoprotein-cholesterol compared to diabetic control (p < 0.001). Mechanistically, induction of T2DM upregulated cardiac expression of TGF-β1, phosphorylated Smad2 and Smad3 proteins, which were downregulated following triple combination therapy (p < 0.001).Conclusion: Triple combination therapy of ALA, gliclazide and ramipril prevented DCM development by inhibiting TGF-β1/Smad pathway. Our findings can be extrapolated to the human heart, which would provide effective additional pharmacological therapy against DCM in T2DM patients.

show abstract

Alpha-lipoic acid and vitamin B complex slow down the changes in mice diabetic cardiomyopathy

Cited by 4 publications

References 42 publications

Protective Effects of α-Lipoic Acid and Chlorogenic Acid on Cadmium-Induced Liver Injury in Three-Yellow Chickens

Protective Effects of α-Lipoic Acid and Chlorogenic Acid on Cadmium-Induced Liver Injury in Three-Yellow Chickens

Chitosan Versus Dapagliflozin in a Diabetic Cardiomyopathy Mouse Model

Combination Therapy of Alpha-Lipoic Acid, Gliclazide and Ramipril Protects Against Development of Diabetic Cardiomyopathy via Inhibition of TGF-β/Smad Pathway

Contact Info

Product

Resources

About